HU-WXDC@EC2612A

Morgan Stanley Downgrades Wyeth Alliance's Profit Forecast and Target Price

Macquarie Recommends Buying Shares of Wuxi Biologics and Wuxi Apptec

Nomura Downgrades WuXi Henlius 2025 Revenue and Profit Forecast and Upgrades 2026 Target Price

WuXi Advanced Therapies Cayman to Hold Board Meeting to Approve 2025 Annual Report

WuXi Xullink Acquires East 曜 Pharmaceutical at a High Premium

WuXi BODYLOGIC Expects Significant Growth in Revenue and Net Profit in 2025 and Announces Acquisition of Tonex Pharmaceuticals

CICC Maintains Buy Rating on WuXi XDC

WuXi Advanced Therapies Anticipates Over 38% Annual Net Profit Growth and Participates in J.P. Morgan Healthcare Conference

WuXi Bodylogics Makes a Cash Offer at HKD4 per Share to Acquire Oncologie

UBS Reiterates Buy Rating and Target Price for Wuxi HoloX Biologics

JPMorgan Sees Opportunities in China's Healthcare Sector, Recommends Biotech and CXO Stocks

WuXi XTL Exercises Options to Issue 1.1133 Million Shares

WuXi Biologics and Its Subsidiary Donate HKD 10 Million for Disaster Relief

C.Sanchez 上调 WuXi Advanced Therapies 目标价 25% 至 90 元

Jiangyin WuXi Advanced Facility Co., Ltd Established

WuXi Advanced Therapies Maintains Strong Order Momentum, Annual Revenue Growth Target Met

WuXi Xelia Announces Issuance of 24.134 Million Shares Under Special Authorization

WuXi PharmaTech Continues to Sell Shares of WuXi Advanced Technology for Approximately HKD 2.346 Billion

Guolian Minsheng Upgrades Profit Forecast for WuXi Advanced Therapy

Zhongyoub Securities First Covers Wuxi Intermediate Biologics with Buy Rating

KO YO GROUP

CH CITY INFRA

GEOTECH HLDGS

PUTIAN COMM

CHINA INFO TECH

AGTECH HOLDINGS

MATRIX HOLDINGS

KFM KINGDOM

SANERGY GROUP

YUNKANG GROUP

520880

513060

588860

513120

512290

02268

516930

520690

159316

510660

513700

588250

159859

Morgan Stanley has lowered the target price for WUXI XDC to 86 yuan, with a rating of "Overweight." Due to a decline in operating profit margins, the bank has reduced its earnings forecast for 2026 to 2030 by 1% to 2%. Nevertheless, it is expected that WUXI XDC's adjusted net profit compound annual growth rate from 2024 to 2027 will reach 36%, higher than global peers, demonstrating the company's profit growth potential and industry leadership

AASTOCKS

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng Health Care ETF(QDII)

ICBCCS SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

WUXI XDC

ChinaAMC SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI 300 Health Care ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Penghua SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Huaan Hang Seng Biotech ETF

Morgan Stanley lowered the target price for WuXi XDC to 86 yuan, rating it as "Overweight."

02359

Macquarie's research report indicates that WuXi AppTec has been included in the U.S. 1260H list, but this list does not constitute an investment ban and mainly affects defense contracts. The report suggests that investors should buy WuXi AppTec during price corrections and maintains its "outperform" rating with a target price of 132 yuan. Meanwhile, WUXI XDC is also recommended with a target price of 73 yuan

WUXI APPTEC

Macquarie urges to buy WuXi AppTec, expected to be included in the US 1260H list without being affected

Nomura Adjusts WuXi XDC Cayman's Price Target to HK$87.73 From HK$82.72, Keeps at Buy

marketscreener

Nomura Adjusts WuXi XDC Cayman's Price Target to HK$87.73 From HK$82.72, Keeps at Buy

02269

Nomura's research report indicates that WUXI BIO is expected to see a revenue increase of 16.7% to RMB 21.8 billion in 2025, exceeding market expectations. The gross margin is expected to improve to 46%, and net profit is projected to grow by 45.3% to RMB 5.7 billion. The firm has raised the target price to HKD 50.54 and maintains a "Buy" rating, believing that its subsidiary WUXI XDC will make a significant contribution to revenue growth

WUXI BIO

Nomura raises WUXI BIO's target price to 50.54 yuan, with preliminary annual performance exceeding expectations

Nomura has raised the target price for WUXI XDC to HKD 87.73, expecting a 47% increase in profits by 2026. Although the revenue and profit forecasts for 2025 have been lowered by 4.5% and 8.7% respectively, the revenue for 2026 is expected to increase by 37% year-on-year to RMB 8.1 billion, mainly benefiting from more projects entering the clinical trial phase. The gross margin is expected to expand to 36.5%, and the operating profit margin will rise to 29.3%

Nomura raises WUXI XDC's target price to 87.73 yuan, expects profit to rise by 47% this year

Wuxi XDC Cayman Inc. and BioDlink International Company Limited have announced the dispatch of a composite document regarding a voluntary cash offer by Citigroup Global Markets Asia Limited for all shares of Wuxi XDC not already owned by the offeror. The update includes the cancellation of all outstanding share options, with further announcements to follow as the transaction progresses.

Reuters

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Proshares UltraShort Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

iShares US Pharma

E Fund CSI New Energy ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

iShares Biotechnology ETF

VG Health

Wuxi XDC Cayman Inc. Sends Out Composite Document for Voluntary Cash Offer

01875

WuXi XDC Cayman Inc. has sent out an offer document for a voluntary cash takeover of TOT BIOPHARM International Co. Ltd. (HK:1875), excluding shares already held by the offeror. The offer starts on 12 February 2026, with key deadlines extending to mid-March. The latest analyst rating for TOT BIOPHARM is a Hold, with a price target of HK$4.50. TOT BIOPHARM focuses on developing oncology and biologic therapies and is listed on the Hong Kong Stock Exchange, with a market cap of HK$3.25B.

Tip Ranks

BIODLINK-B

WuXi XDC Dispatches Offer Document for Cash Takeover of TOT BIOPHARM

688981

83192

02313

JP Morgan listed the companies affected by the appreciation of the RMB on the earnings of Chinese stocks, indicating that a 5% appreciation of the RMB against the USD will negatively impact the net profits of several companies. The affected companies include SHENZHOU INTL, Super Ocean International, SMIC, USISH, COWELL, Longi Green Energy, SINOCERA MATERIAL, Zhejiang Dingli, Sany, XCMG, WUXI BIO, WUXI XDC, Jereh Holdings, and Sinopec Oilfield Service, with an expected impact range of 7% to 15%

SMIC

A BOS RMB MM-R

SHENZHOU INTL

Sany

A BOS RMB MM

SINOCERA MATERIAL

A VP RMB MM

USISH

COWELL

XCMG

JP Morgan lists the Chinese stocks that are most negatively impacted by the appreciation of the RMB (Table)

159570

Goldman Sachs report indicates that the mainland healthcare sector will continue to be strong, but investors need to pay attention to the value of the R&D pipeline. Outperformance depends on key data and earnings visibility. Positive on CDMO companies, upgrading WuXi AppTec and WUXI XDC ratings to "Buy." A selective strategy is recommended for biotech and pharmaceutical companies, recommending SKB BIO-B, HENLIUS, and HANSOH PHARMA. The medical device sector maintains a neutral stance, recommending ANGELALIGN and WEIGAO GROUP. A cautious attitude is taken towards the medical services sector, downgrading HYGEIA HEALTH and JXR ratings

China Universal CNI HK Connect Innovative Drugs Industry ETF

HANSOH PHARMA

SKB BIO-B

KELUN PHARMA

HENLIUS

WEIGAO GROUP

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

HYGEIA HEALTH

WuXi AppTec

ANGELALIGN

Dacheng CSI All Share Health Care Equipment and Services ETF

Hwabao WP CSI Medical Service ETF

Goldman Sachs: The mainland medical sector will rely more on data and profit visibility this year, optimistic about CDMO companies

WuXi XDC Cayman, Inc. (HK:2268) has announced a delay in dispatching a composite offer document for voluntary cash offers for shares not owned by the offeror. The deadline for dispatching the document has been extended from February 4, 2026, to on or before February 13, 2026, pending regulatory consent. This delay is due to the need for more time to finalize financial advice and disclosures. Shareholders are advised to exercise caution regarding the company's securities. The current analyst rating for the stock is a Hold with a price target of HK$65.00.

WuXi XDC Delays Dispatch of Composite Document for Voluntary Cash Offers

WXXWY

WuXi XDC Cayman, Inc. has announced a delay in sending a shareholder circular regarding its offers to acquire shares and cancel options, previously approved by its controlling shareholder, WuXi Biologics. The Hong Kong Stock Exchange has granted a waiver to postpone the circular's dispatch from February 4, 2026, to on or before February 13, 2026. This development is significant for shareholders and potential investors. The latest analyst rating for WuXi XDC stock (HK:2268) is a Hold, with a price target of HK$65.00.

WuXi Biologics

WuXi XDC Delays Shareholder Circular on Offer Transactions After HKEX Waiver

WuXi XDC Cayman Inc. and BioDlink International Company Limited have announced a delay in the dispatch of the composite offer document for the proposed acquisition of TOT BIOPHARM International Co. Ltd. This document will include recommendations from the Independent Board Committee and advice from the Independent Financial Adviser. Further details will be provided in the upcoming document.

TOT BIOPHARM Delays Dispatch of Composite Offer Document

03696

02228

INSILICO fell 11.58%; Jingtao Holdings fell 6.23%, with a transaction volume of HKD 792 million; WuXi Biologics fell 3.36%, with a transaction volume of HKD 442 million; WuXi AppTec fell 0.96%, with a transaction volume of HKD 323 million; WuXi Huilian fell 3.71%, with a market value of HKD 83.2 billion

HK Stock Movers Tracker

INSILICO

XTALPI

Hong Kong Stock Movement: INSILICO approved by FDA but fell 11.58%, leading stocks in the life sciences sector under pressure

WuXi XDC Cayman, Inc. (HK:2268) has scheduled a board meeting on March 23, 2026, to review and approve its annual results for the financial year ending December 31, 2025. This meeting is significant for investors as it will provide insights into the company's financial performance and governance. The latest analyst rating for the stock is a Buy, with a price target of HK$88.00, and the current market cap stands at HK$83.85 billion.

WuXi XDC Schedules Board Meeting to Approve 2025 Annual Results

HU-WXDC@EC2612A(23785.HK)

Morgan Stanley lowered the target price for WuXi XDC to 86 yuan, rating it as "Overweight."

Macquarie urges to buy WuXi AppTec, expected to be included in the US 1260H list without being affected

Nomura Adjusts WuXi XDC Cayman's Price Target to HK$87.73 From HK$82.72, Keeps at Buy

Nomura raises WUXI BIO's target price to 50.54 yuan, with preliminary annual performance exceeding expectations

Nomura raises WUXI XDC's target price to 87.73 yuan, expects profit to rise by 47% this year